ArticleSensors (Basel, Switzerland)2020
Highly Sensitive Chemiluminescence-Based Lateral Flow Immunoassay for Cardiac Troponin I Detection in Human Serum.
Article in Sensors (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 56 citations in OpenAlex.
- Cardiac troponin sensingRSC advances · 2026Article
- Article
- Recent Advances in Monitoring Technologies for Cardiac Troponin I: A Pivotal Biomarker in Cardiovascular Diseases.Biomolecules · 2025Review
- Synergistic action sandwich-type aptasensor based on nanozymes and biological enzymes for ultrasensitive cardiac troponin I determination.Mikrochimica acta · 2025Article
- Aptamer-Based Planar Electric Double-Layer Field-Effect Transistor: A Novel Approach for Sensitive Troponin I Sensing.Biosensors · 2025Article
- Machine learning in point-of-care testing: innovations, challenges, and opportunities.Nature communications · 2025Review
- Analytical and Clinical Performance of High-Sensitivity Cardiac Troponin Point-of-Care Assays as an Aid in the Diagnosis of Myocardial Infarction: A Narrative Review.Emergency medicine international · 2025Review
- Classification and applications of nanomaterialsHeliyon · 2024Review
- Innovative Detection of Biomarkers Based on Chemiluminescent Nanoparticles and a Lensless Optical Sensor.Biosensors · 2024Article
- Methods for detecting of cardiac troponin I biomarkers for myocardial infarction using biosensors: a narrative review of recent research.Journal of thoracic disease · 2023Review
- Recent Advances in Quantum Dot-Based Lateral Flow Immunoassays for the Rapid, Point-of-Care Diagnosis of COVID-19.Biosensors · 2023Review
- Silver-enhanced colloidal gold dip strip immunoassay integrated with smartphone-based colorimetry for sensitive detection of cardiac marker troponin I.Scientific reports · 2022Article
- Highly Sensitive Lanthanide-Doped Nanoparticles-Based Point-of-Care Diagnosis of Human Cardiac Troponin I.International journal of nanomedicine · 2022Article
- Integrating high-performing electrochemical transducers in lateral flow assay.Analytical and bioanalytical chemistry · 2021Article
- Ten Years of Lateral Flow Immunoassay Technique Applications: Trends, Challenges and Future Perspectives.Sensors (Basel, Switzerland) · 2021Review
- Comparison of Single- and Mixed-Sized Gold Nanoparticles on Lateral Flow Assay for Albumin Detection.Biosensors · 2021Article
- Recent Advancements in Enzyme-Based Lateral Flow Immunoassays.Sensors (Basel, Switzerland) · 2021Review
- A Comparative Study of Approaches to Improve the Sensitivity of Lateral Flow Immunoassay of the Antibiotic Lincomycin.Biosensors · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Lateral flow assays (LFAs) have become the most common biosensing platforms for point-of-care testing due to their compliance with the ASSURED (affordable, sensitive, specific, user-friendly, rapid/robust, equipment-free, and deliverable to end-users) guidelines stipulated by the World Health Organization. However, the limited analytical sensitivity and low quantitative capability of conventional LFAs, which use gold nanoparticles (AuNPs) for colorimetric labeling, have prevented high-performance testing. Here, we report the development of a highly sensitive chemiluminescence (CL)-based LFA involving AuNPs conjugated with aldehyde-activated peroxidase and antibody molecules-i.e., AuNP-(ald)HRP-Ab-as a new conjugation scheme for high-performance testing in LFAs. When paired with the CL-based signal readout modality, the AuNP-(ald)HRP-Ab conjugate resulted in 110-fold enhanced sensitivity over the colorimetric response of a typical AuNP-Ab conjugate. To evaluate the performance of the CL-based LFA, we tested it with human cardiac troponin I (cTnI; a standard cardiac biomarker used to diagnose myocardial infarction) in standard and clinical serum samples. Testing the standard samples revealed a detection limit of 5.6 pg·mL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.